Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REL-CT in Idiopathic Pelvic Pain and Endometriosis
NCT06279195Phase 2Withdrawn
- Sponsor
- Endeavor Health
- Start
- Jun 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of relugolix + estradiol + norethindrone in pelvic pain and endometriosis (2 arms), sponsored by Endeavor Health. Primary endpoints: Correlation between post-treatment pelvic pain and baseline uterine contraction frequency at 6 months and Correlation between post-treatment pelvic pain and baseline sensory hypersensitivity Z-score at 6 months. Planned start Jun 2024; status: withdrawn.
02
Drugs
relugolix + estradiol + norethindrone
03
Conditions
pelvic painendometriosis
Beyond the preview
Go deeper on NCT06279195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279195.